{
  "SimulationMappings": [
    {
      "Project": "Raltegravir",
      "Simulation": "Raltegravir 800 mg  (lactose formulation)",
      "Path": "Raltegravir/Raltegravir 800 mg  (lactose formulation)/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Raltegravir 10 mg   (lactose formulation)",
      "Path": "Raltegravir/Raltegravir 10 mg   (lactose formulation)/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Raltegravir 100 mg  (lactose formulation)",
      "Path": "Raltegravir/Raltegravir 100 mg  (lactose formulation)/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Raltegravir 1200 mg   (lactose formulation)",
      "Path": "Raltegravir/Raltegravir 1200 mg   (lactose formulation)/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Raltegravir 1600 mg  (lactose formulation)",
      "Path": "Raltegravir/Raltegravir 1600 mg  (lactose formulation)/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Raltegravir 200 mg   (lactose formulation)",
      "Path": "Raltegravir/Raltegravir 200 mg   (lactose formulation)/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Raltegravir 25 mg  (lactose formulation)",
      "Path": "Raltegravir/Raltegravir 25 mg  (lactose formulation)/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Raltegravir 50 mg  (lactose formulation)",
      "Path": "Raltegravir/Raltegravir 50 mg  (lactose formulation)/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Raltegravir 400mg chewable fasted",
      "Path": "Raltegravir/Raltegravir 400mg chewable fasted/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Raltegravir 400mg filmcoated tablet",
      "Path": "Raltegravir/Raltegravir 400mg filmcoated tablet/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Raltegravir 400mg (lactose formulation)",
      "Path": "Raltegravir/Raltegravir 400mg (lactose formulation)/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Raltegravir 100 mg filmcoated tablet md",
      "Path": "Raltegravir/Raltegravir 100 mg filmcoated tablet md/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Raltegravir 200 mg filmcoated tablet md",
      "Path": "Raltegravir/Raltegravir 200 mg filmcoated tablet md/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Raltegravir 400 mg filmcoated tablet md",
      "Path": "Raltegravir/Raltegravir 400 mg filmcoated tablet md/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Raltegravir 400mg (granules in suspension) lsf",
      "Path": "Raltegravir/Raltegravir 400mg (granules in suspension) lsf/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Raltegravir 400mg chewable fed",
      "Path": "Raltegravir/Raltegravir 400mg chewable fed/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Nachmann 2013 cohort 1 15.2y fed",
      "Path": "Raltegravir/Nachmann 2013 cohort 1 15.2y fed"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Nachmann 2013 cohort 2a 10y fed",
      "Path": "Raltegravir/Nachmann 2013 cohort 2a 10y fed/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Rizk 2015 3.5m meal",
      "Path": "Raltegravir/Rizk 2015 3.5m meal"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Rizk 2015 15m meal",
      "Path": "Raltegravir/Rizk 2015 15m meal/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Larson 2013 8-18y meal",
      "Path": "Raltegravir/Larson 2013 8-18y meal/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Nachmann 2013 cohort 3 - 3.2y fed",
      "Path": "Raltegravir/Nachmann 2013 cohort 3 - 3.2y fed"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Nachmann 2013 cohort 2b 8.8y fed",
      "Path": "Raltegravir/Nachmann 2013 cohort 2b 8.8y fed"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Larson 2013 10.5y meal",
      "Path": "Raltegravir/Larson 2013 10.5y meal"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Larson 2013 9y meal",
      "Path": "Raltegravir/Larson 2013 9y meal/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Larson 2013 3y meal",
      "Path": "Raltegravir/Larson 2013 3y meal/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Larson 2013 15y meal",
      "Path": "Raltegravir/Larson 2013 15y meal/"
    },
    {
      "Project": "Raltegravir",
      "Simulation": "Larson 2013 8-18y fasted",
      "Path": "Raltegravir/Larson 2013 8-18y fasted/"
    }
  ],
  "ObservedDataSets": [
    {
      "Id": "Anderson_2008_Minimal pk interact between etravirine and raltegravir in healthy subjects_fig1.Anderson 2008 Figure 1",
      "Path": "ObservedData/Anderson_2008_Minimal pk interact between etravirine and raltegravir in healthy subjects_fig1.Anderson 2008 Figure 1.csv"
    },
    {
      "Id": "Hanley_2009_Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir_fig1.Hanley 2009 Figure 1",
      "Path": "ObservedData/Hanley_2009_Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir_fig1.Hanley 2009 Figure 1.csv"
    },
    {
      "Id": "Iwamoto_2008_Effects of Omeprazole on Plasma levels of raltegravir_figure 1.Iwamoto 2008 Fig1",
      "Path": "ObservedData/Iwamoto_2008_Effects of Omeprazole on Plasma levels of raltegravir_figure 1.Iwamoto 2008 Fig1.csv"
    },
    {
      "Id": "Iwamoto_2008_Minimal Effects of Ritonavir and Efavirenz on the pk_fig 1.Iwamoto 2008 figure 1",
      "Path": "ObservedData/Iwamoto_2008_Minimal Effects of Ritonavir and Efavirenz on the pk_fig 1.Iwamoto 2008 figure 1.csv"
    },
    {
      "Id": "Kassahun_2007_Metabolism and disposition in humans of Raltegravir _fig2.Figure 2",
      "Path": "ObservedData/Kassahun_2007_Metabolism and disposition in humans of Raltegravir _fig2.Figure 2.csv"
    },
    {
      "Id": "(tablet) Larson_2013_Raltegravir for HIV -1 infected children and adolescents_figure 1.Larson 2013 Figure 1",
      "Path": "ObservedData/(tablet) Larson_2013_Raltegravir for HIV -1 infected children and adolescents_figure 1.Larson 2013 Figure 1.csv"
    },
    {
      "Id": "(tablet chewable ) Larson_2013_Raltegravir for HIV -1 infected children and adolescents_figure 1.Larson 2013 Figure 1",
      "Path": "ObservedData/(tablet chewable ) Larson_2013_Raltegravir for HIV -1 infected children and adolescents_figure 1.Larson 2013 Figure 1.csv"
    },
    {
      "Id": "Nachman_2013_PK safety and 48 week pd of oral raltegravir in hiv1infected children aged 2-19 years_Figure 2 Cohort 3",
      "Path": "ObservedData/Nachman_2013_PK safety and 48 week pd of oral raltegravir in hiv1infected children aged 2-19 years_Figure 2 Cohort 3.csv"
    },
    {
      "Id": "Nachman_2013_PK safety and 48 week pd of oral raltegravir in hiv1infected children aged 2-19 years_Figure 2 Cohort 2b",
      "Path": "ObservedData/Nachman_2013_PK safety and 48 week pd of oral raltegravir in hiv1infected children aged 2-19 years_Figure 2 Cohort 2b.csv"
    },
    {
      "Id": "Nachman_2013_PK safety and 48 week pd of oral raltegravir in hiv1infected children aged 2-19 years_Figure 2 Cohort 2a",
      "Path": "ObservedData/Nachman_2013_PK safety and 48 week pd of oral raltegravir in hiv1infected children aged 2-19 years_Figure 2 Cohort 2a.csv"
    },
    {
      "Id": "Nachman_2013_PK safety and 48 week pd of oral raltegrvir in hiv1infected children aged 2-19 years_Figure 2 Cohort 1",
      "Path": "ObservedData/Nachman_2013_PK safety and 48 week pd of oral raltegrvir in hiv1infected children aged 2-19 years_Figure 2 Cohort 1.csv"
    },
    {
      "Id": "Wenning_2009_Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes_figure 1a.Figure 1",
      "Path": "ObservedData/Wenning_2009_Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes_figure 1a.Figure 1.csv"
    },
    {
      "Id": "Wenning_2008_Lack of a significant drug interaction between raltegravir and tenofovir.Wenning 2008 Figure 1A",
      "Path": "ObservedData/Wenning_2008_Lack of a significant drug interaction between raltegravir and tenofovir.Wenning 2008 Figure 1A.csv"
    },
    {
      "Id": "Wenning_2008_Lack of a significant drug interaction between raltegravir and tenofovir_figure 1b.Wenning 2008 Figure 1B",
      "Path": "ObservedData/Wenning_2008_Lack of a significant drug interaction between raltegravir and tenofovir_figure 1b.Wenning 2008 Figure 1B.csv"
    },
    {
      "Id": "Neely_2010_PK and PD of once-daily raltegravir and atazanavir in healthy volunteers_figure 1a.Neely 2010 Figure 1 A.",
      "Path": "ObservedData/Neely_2010_PK and PD of once-daily raltegravir and atazanavir in healthy volunteers_figure 1a.Neely 2010 Figure 1 A..csv"
    },
    {
      "Id": "Neely_2010_PK and PD of once-daily raltegravir and atazanavir in healthy volunteers Figure 1B.Neely 2010 Figure 1 B",
      "Path": "ObservedData/Neely_2010_PK and PD of once-daily raltegravir and atazanavir in healthy volunteers Figure 1B.Neely 2010 Figure 1 B.csv"
    },
    {
      "Id": "Barau_2013_Characterization of Binding of Raltegravir to Plasma Proteins_figure 1.Barau 2013 Figure 1..total RAL",
      "Path": "ObservedData/Barau_2013_Characterization of Binding of Raltegravir to Plasma Proteins_figure 1.Barau 2013 Figure 1..total RAL.csv"
    },
    {
      "Id": "Barau_2013_Characterization of Binding of Raltegravir to Plasma Proteins_figure 1.Barau 2013 Figure 1. Unbound RAL",
      "Path": "ObservedData/Barau_2013_Characterization of Binding of Raltegravir to Plasma Proteins_figure 1.Barau 2013 Figure 1. Unbound RAL.csv"
    },
    {
      "Id": "UGT1A1 metabolite",
      "Path": "ObservedData/UGT1A1 metabolite.csv"
    },
    {
      "Id": "Kassahun_2007_fraction_ugt1a1",
      "Path": "ObservedData/Kassahun_2007_fraction_ugt1a1.csv"
    },
    {
      "Id": "Rhee 2014 400mg film-coated tablet (fasted)",
      "Path": "ObservedData/Rhee 2014 400mg film-coated tablet (fasted).csv"
    },
    {
      "Id": "Rhee 2014 4x100mg chewable tablet (fasted)",
      "Path": "ObservedData/Rhee 2014 4x100mg chewable tablet (fasted).csv"
    },
    {
      "Id": "Rhee 2014 400mg granules in suspension (fasted)",
      "Path": "ObservedData/Rhee 2014 400mg granules in suspension (fasted).csv"
    },
    {
      "Id": "Rhee 2014 4x100mg chewable tablet (fed)",
      "Path": "ObservedData/Rhee 2014 4x100mg chewable tablet (fed).csv"
    },
    {
      "Id": "Rhee 2014 4x100mg chewable tablet (fed) logscale",
      "Path": "ObservedData/Rhee 2014 4x100mg chewable tablet (fed) logscale.csv"
    },
    {
      "Id": "Rhee 2014 4x100mg chewable tablet (fasted) logscale",
      "Path": "ObservedData/Rhee 2014 4x100mg chewable tablet (fasted) logscale.csv"
    },
    {
      "Id": "Rhee 2014 400mg granules in suspension (fasted) logscale",
      "Path": "ObservedData/Rhee 2014 400mg granules in suspension (fasted) logscale.csv"
    },
    {
      "Id": "Rhee 2014 400mg film-coated tablet (fasted) logscale",
      "Path": "ObservedData/Rhee 2014 400mg film-coated tablet (fasted) logscale.csv"
    },
    {
      "Id": "Markowitz_2006_100 mg bid 10 days",
      "Path": "ObservedData/Markowitz_2006_100 mg bid 10 days.csv"
    },
    {
      "Id": "Markowitz_2006_200 mg bid 10 days",
      "Path": "ObservedData/Markowitz_2006_200 mg bid 10 days.csv"
    },
    {
      "Id": "Markowitz_2006_400 mg bid 10 days",
      "Path": "ObservedData/Markowitz_2006_400 mg bid 10 days.csv"
    },
    {
      "Id": "Markowitz_2006_600 mg bid 10 days",
      "Path": "ObservedData/Markowitz_2006_600 mg bid 10 days.csv"
    },
    {
      "Id": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 9",
      "Path": "ObservedData/Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 9.csv"
    },
    {
      "Id": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 10",
      "Path": "ObservedData/Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 10.csv"
    },
    {
      "Id": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 11",
      "Path": "ObservedData/Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 11.csv"
    },
    {
      "Id": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 12",
      "Path": "ObservedData/Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 12.csv"
    },
    {
      "Id": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 13",
      "Path": "ObservedData/Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 13.csv"
    },
    {
      "Id": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 14",
      "Path": "ObservedData/Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 14.csv"
    },
    {
      "Id": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 15",
      "Path": "ObservedData/Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 15.csv"
    },
    {
      "Id": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 16",
      "Path": "ObservedData/Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 16.csv"
    },
    {
      "Id": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 17",
      "Path": "ObservedData/Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 17.csv"
    },
    {
      "Id": "PK-Parameter",
      "Path": "ObservedData/PK-Parameters.csv",
      "Type": "PKRatio"
    }
  ],
  "Plots": {
    "PlotSettings": {
      "ChartWidth": 500,
      "ChartHeight": 400,
      "Fonts": {
        "AxisSize": 11,
        "LegendSize": 9,
        "OriginSize": 9,
        "FontFamilyName": "Arial",
        "WatermarkSize": 40
      }
    },
    "AxesSettings": {
      "ComparisonTimeProfile": [
        {
          "Unit": "h",
          "Dimension": "Time",
          "Type": "X",
          "GridLines": false,
          "Scaling": "Linear"
        },
        {
          "Unit": "µg/l",
          "Dimension": "Concentration (mass)",
          "Type": "Y",
          "GridLines": false,
          "Scaling": "Log"
        }
      ],
      "DDIRatioPlotsPredictedVsObserved": [
        {
          "Unit": "",
          "Dimension": "Dimensionless",
          "Type": "X",
          "GridLines": false,
          "Scaling": "Log"
        },
        {
          "Unit": "",
          "Dimension": "Dimensionless",
          "Type": "Y",
          "GridLines": false,
          "Scaling": "Log"
        }
      ],
      "DDIRatioPlotsResidualsVsObserved": [
        {
          "Unit": "",
          "Dimension": "Dimensionless",
          "Type": "X",
          "GridLines": false,
          "Scaling": "Log"
        },
        {
          "Unit": "",
          "Dimension": "Dimensionless",
          "Type": "Y",
          "GridLines": false,
          "Scaling": "Linear"
        }
      ],
      "GOFMergedPlotsPredictedVsObserved": [
        {
          "Unit": "µg/l",
          "Dimension": "Concentration (mass)",
          "Type": "X",
          "GridLines": false,
          "Scaling": "Log"
        },
        {
          "Unit": "µg/l",
          "Dimension": "Concentration (mass)",
          "Type": "Y",
          "GridLines": false,
          "Scaling": "Log"
        }
      ],
      "GOFMergedPlotsResidualsOverTime": [
        {
          "Unit": "h",
          "Dimension": "Time",
          "Type": "X",
          "GridLines": false,
          "Scaling": "Linear"
        },
        {
          "Unit": "",
          "Dimension": "Dimensionless",
          "Type": "Y",
          "GridLines": false,
          "Scaling": "Linear"
        }
      ],
      "PKRatioPlots": [
        {
          "Unit": "year(s)",
          "Dimension": "Age",
          "Type": "X",
          "GridLines": false,
          "Scaling": "Log"
        },
        {
          "Unit": "",
          "Dimension": "Dimensionless",
          "Type": "Y",
          "GridLines": false,
          "Scaling": "Log"
        }
      ]
    },
    "PKRatioPlots": [
      {
        "Title": "Overall predictivity of the Raltegravir PBPK model. Open circles represent mean ratios of PBPK predicted AUC over observed AUC of all drugs in children 1 month to 18 years old. Blue dashed lines and red dotted lines represent the 1.5-fold and 2-fold error, respectively.",
        "PKParameter": "AUC",
        "SectionId": 2,
        "Groups": [
          {
            "Caption": "Raltegravir",
            "Color": "#000000",
            "Symbol": "Circle",
            "PKRatios": [
              {
                "Project": "Raltegravir",
                "Simulation": "Larson 2013 15y meal",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "PK-Parameter",
                "ObservedDataRecordId": 5433
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Larson 2013 10.5y meal",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "PK-Parameter",
                "ObservedDataRecordId": 5309
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Larson 2013 9y meal",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "PK-Parameter",
                "ObservedDataRecordId": 5308
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Larson 2013 3y meal",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "PK-Parameter",
                "ObservedDataRecordId": 5307
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Nachmann 2013 cohort 1 15.2y fed",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "PK-Parameter",
                "ObservedDataRecordId": 5303
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Nachmann 2013 cohort 2a 10y fed",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "PK-Parameter",
                "ObservedDataRecordId": 5304
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Nachmann 2013 cohort 2b 8.8y fed",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "PK-Parameter",
                "ObservedDataRecordId": 5305
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Nachmann 2013 cohort 3 - 3.2y fed",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "PK-Parameter",
                "ObservedDataRecordId": 5306
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Rizk 2015 15m meal",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "PK-Parameter",
                "ObservedDataRecordId": 5302
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Rizk 2015 3.5m meal",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "PK-Parameter",
                "ObservedDataRecordId": 5301
              }
            ]
          }
        ]
      }
    ],
    "GOFMergedPlots": [
      {
        "Title": "Goodness-of-fit visual diagnostic plots of the raltegravir PBPK model performance: observed versus individually predicted plasma concentration versus time of all adult data.",
        "SectionId": 44,
        "PlotType": "predictedVsObserved",
        "Groups": [
          {
            "Caption": "Raltegravir lactose formulation",
            "Symbol": "Triangle",
            "OutputMappings": [
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 10 mg   (lactose formulation)",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 9",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 25 mg  (lactose formulation)",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 10",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 50 mg  (lactose formulation)",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 11",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 100 mg  (lactose formulation)",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 12",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 200 mg   (lactose formulation)",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 13",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 400mg (lactose formulation)",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 14",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 400mg (lactose formulation)",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Wenning_2009_Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes_figure 1a.Figure 1",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 800 mg  (lactose formulation)",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 15",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 1200 mg   (lactose formulation)",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 16",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 1600 mg  (lactose formulation)",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 17",
                "Color": "#000000"
              }
            ]
          },
          {
            "Caption": "Raltegravir filmcoated tablet",
            "Symbol": "Circle",
            "OutputMappings": [
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 100 mg filmcoated tablet md",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Markowitz_2006_100 mg bid 10 days",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 200 mg filmcoated tablet md",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Markowitz_2006_200 mg bid 10 days",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 200 mg filmcoated tablet md",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Kassahun_2007_Metabolism and disposition in humans of Raltegravir _fig2.Figure 2",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 400 mg filmcoated tablet md",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Markowitz_2006_400 mg bid 10 days",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 400mg filmcoated tablet",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Rhee 2014 400mg film-coated tablet (fasted) logscale",
                "Color": "#000000"
              }
            ]
          },
          {
            "Caption": "Raltegravir chewable tablet",
            "Symbol": "Asterisk",
            "OutputMappings": [
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 400mg chewable fasted",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Rhee 2014 4x100mg chewable tablet (fasted) logscale",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 400mg chewable fed",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Rhee 2014 4x100mg chewable tablet (fed) logscale",
                "Color": "#000000"
              }
            ]
          },
          {
            "Caption": "Raltegravir granules in suspension",
            "Symbol": "Square",
            "OutputMappings": [
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 400mg (granules in suspension) lsf",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Rhee 2014 400mg granules in suspension (fasted) logscale",
                "Color": "#000000"
              }
            ]
          }
        ]
      },
      {
        "Title": "Goodness-of-fit visual diagnostic plots of the raltegravir PBPK model performance: weighted residuals versus time of all adult data.",
        "SectionId": 44,
        "PlotType": "residualsOverTime",
        "Groups": [
          {
            "Caption": "Raltegravir lactose formulation",
            "Symbol": "Triangle",
            "OutputMappings": [
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 10 mg   (lactose formulation)",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 9",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 25 mg  (lactose formulation)",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 10",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 50 mg  (lactose formulation)",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 11",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 100 mg  (lactose formulation)",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 12",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 200 mg   (lactose formulation)",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 13",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 400mg (lactose formulation)",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 14",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 400mg (lactose formulation)",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Wenning_2009_Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes_figure 1a.Figure 1",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 800 mg  (lactose formulation)",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 15",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 1200 mg   (lactose formulation)",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 16",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 1600 mg  (lactose formulation)",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 17",
                "Color": "#000000"
              }
            ]
          },
          {
            "Caption": "Raltegravir filmcoated tablet",
            "Symbol": "Circle",
            "OutputMappings": [
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 100 mg filmcoated tablet md",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Markowitz_2006_100 mg bid 10 days",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 200 mg filmcoated tablet md",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Markowitz_2006_200 mg bid 10 days",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 200 mg filmcoated tablet md",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Kassahun_2007_Metabolism and disposition in humans of Raltegravir _fig2.Figure 2",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 400 mg filmcoated tablet md",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Markowitz_2006_400 mg bid 10 days",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 400mg filmcoated tablet",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Rhee 2014 400mg film-coated tablet (fasted) logscale",
                "Color": "#000000"
              }
            ]
          },
          {
            "Caption": "Raltegravir chewable tablet",
            "Symbol": "Asterisk",
            "OutputMappings": [
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 400mg chewable fasted",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Rhee 2014 4x100mg chewable tablet (fasted) logscale",
                "Color": "#000000"
              },
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 400mg chewable fed",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Rhee 2014 4x100mg chewable tablet (fed) logscale",
                "Color": "#000000"
              }
            ]
          },
          {
            "Caption": "Raltegravir granules in suspension",
            "Symbol": "Square",
            "OutputMappings": [
              {
                "Project": "Raltegravir",
                "Simulation": "Raltegravir 400mg (granules in suspension) lsf",
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "Rhee 2014 400mg granules in suspension (fasted) logscale",
                "Color": "#000000"
              }
            ]
          }
        ]
      }
    ],
    "TimeProfile": [
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 400mg chewable fasted",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 400mg chewable fasted-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 400mg chewable fasted|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Rhee 2014 4x100mg chewable tablet (fasted) logscale-Raltegravir-Peripheral Venous Blood-Plasma-µm/L(1)",
              "X": "Rhee 2014 4x100mg chewable tablet (fasted) logscale|h(1)",
              "Y": "Rhee 2014 4x100mg chewable tablet (fasted) logscale|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|µm/L(1)",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "OriginText": "Raltegravir\nRaltegravir 400mg chewable fasted\n2019-07-22 15:24"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 400mg chewable fasted",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 400mg chewable fasted-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 400mg chewable fasted|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Rhee 2014 4x100mg chewable tablet (fasted) logscale-Raltegravir-Peripheral Venous Blood-Plasma-µm/L(1)",
              "X": "Rhee 2014 4x100mg chewable tablet (fasted) logscale|h(1)",
              "Y": "Rhee 2014 4x100mg chewable tablet (fasted) logscale|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|µm/L(1)",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis 1",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "OriginText": "Raltegravir\nRaltegravir 400mg chewable fasted\n2019-07-22 15:24"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 400mg chewable fed",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 400mg chewable fed-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 400mg chewable fed|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Rhee 2014 4x100mg chewable tablet (fed) logscale-Raltegravir-Peripheral Venous Blood-Plasma-µm/L(3)",
              "X": "Rhee 2014 4x100mg chewable tablet (fed) logscale|h(1)",
              "Y": "Rhee 2014 4x100mg chewable tablet (fed) logscale|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|µm/L(3)",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 600,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "OriginText": "Raltegravir\nRaltegravir 400mg chewable fed\n2019-07-22 15:24"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 400mg chewable fed",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 400mg chewable fed-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 400mg chewable fed|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Rhee 2014 4x100mg chewable tablet (fed) logscale-Raltegravir-Peripheral Venous Blood-Plasma-µm/L(3)",
              "X": "Rhee 2014 4x100mg chewable tablet (fed) logscale|h(1)",
              "Y": "Rhee 2014 4x100mg chewable tablet (fed) logscale|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|µm/L(3)",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis 1",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 600,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "OriginText": "Raltegravir\nRaltegravir 400mg chewable fed\n2019-07-22 15:24"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 100 mg filmcoated tablet md",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "Min": 206.2325,
              "Max": 238.906,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "Min": 17.35518,
              "Max": 1027.024,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Markowitz_2006_Antiretroviral activity pk and tolerability of mk-0518-Raltegravir-Peripheral Venous Blood-Plasma-nM/L",
              "X": "Markowitz_2006_100 mg bid 10 days|h(2)",
              "Y": "Markowitz_2006_100 mg bid 10 days|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM/L",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Raltegravir 100 mg filmcoated tablet md-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 100 mg filmcoated tablet md|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            }
          ],
          "Name": "Time Profile Analysis",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir\nRaltegravir 100 mg filmcoated tablet md\n2019-07-22 15:25"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 100 mg filmcoated tablet md",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "Min": 206.2325,
              "Max": 238.906,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "Min": 17.35518,
              "Max": 1027.024,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Markowitz_2006_Antiretroviral activity pk and tolerability of mk-0518-Raltegravir-Peripheral Venous Blood-Plasma-nM/L",
              "X": "Markowitz_2006_100 mg bid 10 days|h(2)",
              "Y": "Markowitz_2006_100 mg bid 10 days|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM/L",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Raltegravir 100 mg filmcoated tablet md-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 100 mg filmcoated tablet md|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            }
          ],
          "Name": "Time Profile Analysis 1",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir\nRaltegravir 100 mg filmcoated tablet md\n2019-07-22 15:25"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 200 mg filmcoated tablet md",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 200 mg filmcoated tablet md-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 200 mg filmcoated tablet md|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Markowitz_2006_Antiretroviral activity pk and tolerability of mk-0518 1-Raltegravir-Peripheral Venous Blood-Plasma-nM/L(1)",
              "X": "Markowitz_2006_200 mg bid 10 days|h(2)",
              "Y": "Markowitz_2006_200 mg bid 10 days|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM/L(1)",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Kassahun_2007_Metabolism and disposition in humans of Raltegravir _fig2.Figure 2-Raltegravir-Peripheral Venous Blood-Plasma-nM",
              "X": "Kassahun_2007_Metabolism and disposition in humans of Raltegravir _fig2.Figure 2|h(1)",
              "Y": "Kassahun_2007_Metabolism and disposition in humans of Raltegravir _fig2.Figure 2|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis",
          "OriginText": "Raltegravir_\nRaltegravir 200 mg filmcoated tablet md\n2019-07-17 13:29"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 200 mg filmcoated tablet md",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 200 mg filmcoated tablet md-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 200 mg filmcoated tablet md|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Markowitz_2006_Antiretroviral activity pk and tolerability of mk-0518 1-Raltegravir-Peripheral Venous Blood-Plasma-nM/L(1)",
              "X": "Markowitz_2006_200 mg bid 10 days|h(2)",
              "Y": "Markowitz_2006_200 mg bid 10 days|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM/L(1)",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Kassahun_2007_Metabolism and disposition in humans of Raltegravir _fig2.Figure 2-Raltegravir-Peripheral Venous Blood-Plasma-nM",
              "X": "Kassahun_2007_Metabolism and disposition in humans of Raltegravir _fig2.Figure 2|h(1)",
              "Y": "Kassahun_2007_Metabolism and disposition in humans of Raltegravir _fig2.Figure 2|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis 1",
          "OriginText": "Raltegravir_\nRaltegravir 200 mg filmcoated tablet md\n2019-07-17 13:29"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 400 mg filmcoated tablet md",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "Min": 207.0163,
              "Max": 237.629,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "Min": 47.74055,
              "Max": 4111.514,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 400 mg filmcoated tablet md-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 400 mg filmcoated tablet md|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Markowitz_2006_Antiretroviral activity pk and tolerability of mk-0518 2-Raltegravir-Peripheral Venous Blood-Plasma-nM/L(2)",
              "X": "Markowitz_2006_400 mg bid 10 days|h(2)",
              "Y": "Markowitz_2006_400 mg bid 10 days|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM/L(2)",
              "CurveOptions": {
                "Color": "#008000",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 400 mg filmcoated tablet md\n2019-07-17 13:30"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 400 mg filmcoated tablet md",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "Min": 207.0163,
              "Max": 237.629,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "Min": 47.74055,
              "Max": 4111.514,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 400 mg filmcoated tablet md-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 400 mg filmcoated tablet md|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Markowitz_2006_Antiretroviral activity pk and tolerability of mk-0518 2-Raltegravir-Peripheral Venous Blood-Plasma-nM/L(2)",
              "X": "Markowitz_2006_400 mg bid 10 days|h(2)",
              "Y": "Markowitz_2006_400 mg bid 10 days|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM/L(2)",
              "CurveOptions": {
                "Color": "#008000",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis 1",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 400 mg filmcoated tablet md\n2019-07-17 13:30"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 400mg filmcoated tablet",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 400mg filmcoated tablet-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 400mg filmcoated tablet|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Rhee 2014 400mg film-coated tablet (fasted) logscale-Raltegravir-Peripheral Venous Blood-Plasma-µm/L",
              "X": "Rhee 2014 400mg film-coated tablet (fasted) logscale|h(1)",
              "Y": "Rhee 2014 400mg film-coated tablet (fasted) logscale|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|µm/L",
              "CurveOptions": {
                "Color": "#008000",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "OriginText": "Raltegravir_\nRaltegravir 400mg filmcoated tablet\n2019-07-17 13:30"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 400mg filmcoated tablet",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 400mg filmcoated tablet-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 400mg filmcoated tablet|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Rhee 2014 400mg film-coated tablet (fasted) logscale-Raltegravir-Peripheral Venous Blood-Plasma-µm/L",
              "X": "Rhee 2014 400mg film-coated tablet (fasted) logscale|h(1)",
              "Y": "Rhee 2014 400mg film-coated tablet (fasted) logscale|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|µm/L",
              "CurveOptions": {
                "Color": "#008000",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis 1",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "OriginText": "Raltegravir_\nRaltegravir 400mg filmcoated tablet\n2019-07-17 13:30"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 400mg (granules in suspension) lsf",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 400mg (granules in suspension) lsf-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 400mg (granules in suspension) lsf|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Rhee 2014 400mg granules in suspension (fasted) logscale-Raltegravir-Peripheral Venous Blood-Plasma-µm/L(2)",
              "X": "Rhee 2014 400mg granules in suspension (fasted) logscale|h(1)",
              "Y": "Rhee 2014 400mg granules in suspension (fasted) logscale|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|µm/L(2)",
              "CurveOptions": {
                "Color": "#FF8000",
                "LegendIndex": 10,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "RightInside",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 400mg (granules in suspension) lsf\n2019-07-17 08:47"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 400mg (granules in suspension) lsf",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 400mg (granules in suspension) lsf-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 400mg (granules in suspension) lsf|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Rhee 2014 400mg granules in suspension (fasted) logscale-Raltegravir-Peripheral Venous Blood-Plasma-µm/L(2)",
              "X": "Rhee 2014 400mg granules in suspension (fasted) logscale|h(1)",
              "Y": "Rhee 2014 400mg granules in suspension (fasted) logscale|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|µm/L(2)",
              "CurveOptions": {
                "Color": "#FF8000",
                "LegendIndex": 10,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis 1",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 400mg (granules in suspension) lsf\n2019-07-17 08:47"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 10 mg   (lactose formulation)",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 10 mg   (lactose formulation)-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 10 mg   (lactose formulation)|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 9-Raltegravir-Peripheral Venous Blood-Plasma-nM",
              "X": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 9|h(1)",
              "Y": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 9|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 10 mg   (lactose formulation)\n2019-07-18 14:09"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 10 mg   (lactose formulation)",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 10 mg   (lactose formulation)-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 10 mg   (lactose formulation)|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 9-Raltegravir-Peripheral Venous Blood-Plasma-nM",
              "X": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 9|h(1)",
              "Y": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 9|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis 1",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 10 mg   (lactose formulation)\n2019-07-18 14:09"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 100 mg  (lactose formulation)",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 12-Raltegravir-Peripheral Venous Blood-Plasma-nM",
              "X": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 12|h(1)",
              "Y": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 12|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Raltegravir 100 mg  (lactose formulation)-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 100 mg  (lactose formulation)|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            }
          ],
          "Name": "Time Profile Analysis",
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 100 mg  (lactose formulation)\n2019-07-17 13:31"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 100 mg  (lactose formulation)",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 12-Raltegravir-Peripheral Venous Blood-Plasma-nM",
              "X": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 12|h(1)",
              "Y": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 12|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Raltegravir 100 mg  (lactose formulation)-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 100 mg  (lactose formulation)|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            }
          ],
          "Name": "Time Profile Analysis 1",
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 100 mg  (lactose formulation)\n2019-07-17 13:31"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 1200 mg   (lactose formulation)",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 1200 mg   (lactose formulation)-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 1200 mg   (lactose formulation)|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 16-Raltegravir-Peripheral Venous Blood-Plasma-nM",
              "X": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 16|h(1)",
              "Y": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 16|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 1200 mg   (lactose formulation)\n2019-07-17 13:31"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 1200 mg   (lactose formulation)",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 1200 mg   (lactose formulation)-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 1200 mg   (lactose formulation)|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 16-Raltegravir-Peripheral Venous Blood-Plasma-nM",
              "X": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 16|h(1)",
              "Y": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 16|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis 1",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 1200 mg   (lactose formulation)\n2019-07-17 13:31"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 1600 mg  (lactose formulation)",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 1600 mg  (lactose formulation)-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 1600 mg  (lactose formulation)|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 17-Raltegravir-Peripheral Venous Blood-Plasma-nM",
              "X": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 17|h(1)",
              "Y": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 17|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 1600 mg  (lactose formulation)\n2019-07-16 17:54"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 1600 mg  (lactose formulation)",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 1600 mg  (lactose formulation)-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 1600 mg  (lactose formulation)|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 17-Raltegravir-Peripheral Venous Blood-Plasma-nM",
              "X": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 17|h(1)",
              "Y": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 17|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis 1",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 1600 mg  (lactose formulation)\n2019-07-16 17:54"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 200 mg   (lactose formulation)",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 200 mg   (lactose formulation)-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 200 mg   (lactose formulation)|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 13-Raltegravir-Peripheral Venous Blood-Plasma-nM",
              "X": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 13|h(1)",
              "Y": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 13|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM",
              "CurveOptions": {
                "Color": "#008000",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 200 mg   (lactose formulation)\n2019-07-16 17:54"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 200 mg   (lactose formulation)",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 200 mg   (lactose formulation)-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 200 mg   (lactose formulation)|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 13-Raltegravir-Peripheral Venous Blood-Plasma-nM",
              "X": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 13|h(1)",
              "Y": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 13|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM",
              "CurveOptions": {
                "Color": "#008000",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis 1",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 200 mg   (lactose formulation)\n2019-07-16 17:54"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 25 mg  (lactose formulation)",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 25 mg  (lactose formulation)-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 25 mg  (lactose formulation)|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 10-Raltegravir-Peripheral Venous Blood-Plasma-nM",
              "X": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 10|h(1)",
              "Y": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 10|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 25 mg  (lactose formulation)\n2019-07-17 15:03"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 25 mg  (lactose formulation)",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 25 mg  (lactose formulation)-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 25 mg  (lactose formulation)|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 10-Raltegravir-Peripheral Venous Blood-Plasma-nM",
              "X": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 10|h(1)",
              "Y": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 10|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis 1",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 25 mg  (lactose formulation)\n2019-07-17 15:03"
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 400mg (lactose formulation)",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 400mg (lactose formulation)-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 400mg (lactose formulation)|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 14-Raltegravir-Peripheral Venous Blood-Plasma-nM",
              "X": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 14|h(1)",
              "Y": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 14|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 9,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Wenning_2009_Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes_figure 1a.Figure 1-Raltegravir-Peripheral Venous Blood-Plasma-µg/L",
              "X": "Wenning_2009_Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes_figure 1a.Figure 1|h(1)",
              "Y": "Wenning_2009_Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes_figure 1a.Figure 1|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|µg/L",
              "CurveOptions": {
                "Color": "#C04000",
                "LegendIndex": 8,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 400mg (lactose formulation)\n2019-07-16 17:55",
          "PreviewSettings": true
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 400mg (lactose formulation)",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 400mg (lactose formulation)-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 400mg (lactose formulation)|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 14-Raltegravir-Peripheral Venous Blood-Plasma-nM",
              "X": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 14|h(1)",
              "Y": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 14|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 9,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Wenning_2009_Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes_figure 1a.Figure 1-Raltegravir-Peripheral Venous Blood-Plasma-µg/L",
              "X": "Wenning_2009_Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes_figure 1a.Figure 1|h(1)",
              "Y": "Wenning_2009_Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes_figure 1a.Figure 1|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|µg/L",
              "CurveOptions": {
                "Color": "#C04000",
                "LegendIndex": 8,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis 1",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 400mg (lactose formulation)\n2019-07-16 17:55",
          "PreviewSettings": true
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 50 mg  (lactose formulation)",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 50 mg  (lactose formulation)-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 50 mg  (lactose formulation)|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 11-Raltegravir-Peripheral Venous Blood-Plasma-nM",
              "X": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 11|h(1)",
              "Y": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 11|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 50 mg  (lactose formulation)\n2019-07-16 17:55",
          "PreviewSettings": true
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 50 mg  (lactose formulation)",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 50 mg  (lactose formulation)-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 50 mg  (lactose formulation)|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 11-Raltegravir-Peripheral Venous Blood-Plasma-nM",
              "X": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 11|h(1)",
              "Y": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 11|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis 1",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 50 mg  (lactose formulation)\n2019-07-16 17:55",
          "PreviewSettings": true
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 800 mg  (lactose formulation)",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 800 mg  (lactose formulation)-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 800 mg  (lactose formulation)|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 15-Raltegravir-Peripheral Venous Blood-Plasma-nM",
              "X": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 15|h(1)",
              "Y": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 15|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 800 mg  (lactose formulation)\n2019-07-17 08:46",
          "PreviewSettings": true
        }
      },
      {
        "SectionId": 42,
        "Project": "Raltegravir",
        "Simulation": "Raltegravir 800 mg  (lactose formulation)",
        "Plot": {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "Raltegravir 800 mg  (lactose formulation)-Raltegravir-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "Raltegravir 800 mg  (lactose formulation)|Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 15-Raltegravir-Peripheral Venous Blood-Plasma-nM",
              "X": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 15|h(1)",
              "Y": "Iwamoto_2008_Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Iwamoto 2008 Fig 2 final table 15|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|nM",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis 1",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nRaltegravir 800 mg  (lactose formulation)\n2019-07-17 08:46",
          "PreviewSettings": true
        }
      },
      {
        "SectionId": 32,
        "Project": "Raltegravir",
        "Simulation": "Larson 2013 8-18y meal",
        "Plot": {
          "Type": "TimeProfile",
          "Analysis": {
            "Fields": [
              {
                "Name": "Concentration-Larson 2013 8-18y meal-Raltegravir-Organism-Peripheral Venous Blood-Plasma",
                "Dimension": "Concentration (molar)",
                "Scaling": "Log",
                "Unit": "µg/l",
                "QuantityPath": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "QuantityType": "Drug, Observer",
                "Color": "#000000",
                "Area": "DataArea"
              }
            ],
            "Statistics": [
              {
                "Id": "GeometricMean",
                "LineStyle": "Solid"
              },
              {
                "Id": "Range90",
                "LineStyle": "Solid"
              }
            ]
          },
          "ObservedDataCollection": {
            "ObservedData": [
              "(tablet) Larson_2013_Raltegravir for HIV -1 infected children and adolescents_figure 1.Larson 2013 Figure 1"
            ],
            "ApplyGrouping": false,
            "CurveOptions": [
              {
                "Caption": "(tablet) Larson_2013_Raltegravir for HIV -1 infected children and adolescents_figure 1.Larson 2013 Figure 1-Raltegravir-Peripheral Venous Blood-Plasma-ng/mL",
                "Path": "(tablet) Larson_2013_Raltegravir for HIV -1 infected children and adolescents_figure 1.Larson 2013 Figure 1|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|ng/mL",
                "CurveOptions": {
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              }
            ]
          },
          "XAxisSettings": {
            "AutoRange": true
          },
          "YAxisSettings": {
            "AutoRange": true
          },
          "SecondaryYAxisSettings": [],
          "Name": "Time Profile Analysis",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "Bottom",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nLarson 2013 8-18y meal\n2019-07-17 13:42",
          "PreviewSettings": true
        }
      },
      {
        "SectionId": 32,
        "Project": "Raltegravir",
        "Simulation": "Larson 2013 8-18y meal",
        "Plot": {
          "Type": "TimeProfile",
          "Analysis": {
            "Fields": [
              {
                "Name": "Concentration-Larson 2013 8-18y meal-Raltegravir-Organism-Peripheral Venous Blood-Plasma",
                "Dimension": "Concentration (molar)",
                "Scaling": "Linear",
                "Unit": "µg/l",
                "QuantityPath": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "QuantityType": "Drug, Observer",
                "Color": "#000000",
                "Area": "DataArea"
              }
            ],
            "Statistics": [
              {
                "Id": "GeometricMean",
                "LineStyle": "Solid"
              },
              {
                "Id": "Range90",
                "LineStyle": "Solid"
              }
            ]
          },
          "ObservedDataCollection": {
            "ObservedData": [
              "(tablet) Larson_2013_Raltegravir for HIV -1 infected children and adolescents_figure 1.Larson 2013 Figure 1"
            ],
            "ApplyGrouping": false,
            "CurveOptions": [
              {
                "Caption": "(tablet) Larson_2013_Raltegravir for HIV -1 infected children and adolescents_figure 1.Larson 2013 Figure 1-Raltegravir-Peripheral Venous Blood-Plasma-ng/mL",
                "Path": "(tablet) Larson_2013_Raltegravir for HIV -1 infected children and adolescents_figure 1.Larson 2013 Figure 1|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|ng/mL",
                "CurveOptions": {
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              }
            ]
          },
          "XAxisSettings": {
            "AutoRange": true
          },
          "YAxisSettings": {
            "AutoRange": true
          },
          "SecondaryYAxisSettings": [],
          "Name": "Time Profile Analysis 1",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "Bottom",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nLarson 2013 8-18y meal\n2019-07-17 13:42",
          "PreviewSettings": true
        }
      },
      {
        "SectionId": 32,
        "Project": "Raltegravir",
        "Simulation": "Larson 2013 8-18y fasted",
        "Plot": {
          "Type": "TimeProfile",
          "Analysis": {
            "Fields": [
              {
                "Name": "Concentration-Larson 2013 8-18y meal-Raltegravir-Organism-Peripheral Venous Blood-Plasma",
                "Dimension": "Concentration (molar)",
                "Scaling": "Log",
                "Unit": "µg/l",
                "QuantityPath": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "QuantityType": "Drug, Observer",
                "Color": "#000000",
                "Area": "DataArea"
              }
            ],
            "Statistics": [
              {
                "Id": "GeometricMean",
                "LineStyle": "Solid"
              },
              {
                "Id": "Range90",
                "LineStyle": "Solid"
              }
            ]
          },
          "ObservedDataCollection": {
            "ObservedData": [
              "(tablet) Larson_2013_Raltegravir for HIV -1 infected children and adolescents_figure 1.Larson 2013 Figure 1"
            ],
            "ApplyGrouping": false,
            "CurveOptions": [
              {
                "Caption": "(tablet) Larson_2013_Raltegravir for HIV -1 infected children and adolescents_figure 1.Larson 2013 Figure 1-Raltegravir-Peripheral Venous Blood-Plasma-ng/mL",
                "Path": "(tablet) Larson_2013_Raltegravir for HIV -1 infected children and adolescents_figure 1.Larson 2013 Figure 1|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|ng/mL",
                "CurveOptions": {
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              }
            ]
          },
          "XAxisSettings": {
            "AutoRange": false
          },
          "YAxisSettings": {
            "AutoRange": false
          },
          "SecondaryYAxisSettings": [],
          "Name": "Time Profile Analysis",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "Bottom",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nLarson 2013 8-18y fasted\n2019-07-22 10:20",
          "PreviewSettings": true
        }
      },
      {
        "SectionId": 32,
        "Project": "Raltegravir",
        "Simulation": "Larson 2013 8-18y fasted",
        "Plot": {
          "Type": "TimeProfile",
          "Analysis": {
            "Fields": [
              {
                "Name": "Concentration-Larson 2013 8-18y meal-Raltegravir-Organism-Peripheral Venous Blood-Plasma",
                "Dimension": "Concentration (molar)",
                "Scaling": "Linear",
                "Unit": "µg/l",
                "QuantityPath": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "QuantityType": "Drug, Observer",
                "Color": "#000000",
                "Area": "DataArea"
              }
            ],
            "Statistics": [
              {
                "Id": "GeometricMean",
                "LineStyle": "Solid"
              },
              {
                "Id": "Range90",
                "LineStyle": "Solid"
              }
            ]
          },
          "ObservedDataCollection": {
            "ObservedData": [
              "(tablet) Larson_2013_Raltegravir for HIV -1 infected children and adolescents_figure 1.Larson 2013 Figure 1"
            ],
            "ApplyGrouping": false,
            "CurveOptions": [
              {
                "Caption": "(tablet) Larson_2013_Raltegravir for HIV -1 infected children and adolescents_figure 1.Larson 2013 Figure 1-Raltegravir-Peripheral Venous Blood-Plasma-ng/mL",
                "Path": "(tablet) Larson_2013_Raltegravir for HIV -1 infected children and adolescents_figure 1.Larson 2013 Figure 1|ObservedData|Peripheral Venous Blood|Plasma|Raltegravir|ng/mL",
                "CurveOptions": {
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              }
            ]
          },
          "XAxisSettings": {
            "AutoRange": false
          },
          "YAxisSettings": {
            "AutoRange": false
          },
          "SecondaryYAxisSettings": [],
          "Name": "Time Profile Analysis 1",
          "FontAndSize": {
            "ChartWidth": 600,
            "ChartHeight": 400,
            "Fonts": {
              "AxisSize": 10,
              "LegendSize": 8,
              "TitleSize": 16,
              "DescriptionSize": 12,
              "OriginSize": 8,
              "FontFamilyName": "Microsoft Sans Serif",
              "WatermarkSize": 32
            }
          },
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "Bottom",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "OriginText": "Raltegravir_\nLarson 2013 8-18y fasted\n2019-07-22 10:20",
          "PreviewSettings": true
        }
      }
    ]
  },
  "Inputs": [
    {
      "SectionId": 40,
      "Path": "Inputs/Raltegravir/Compound/Raltegravir.md"
    }
  ],
  "Sections": [
    {
      "Id": 2,
      "Title": "Chapter 1: Introduction to Pediatric Translation and UGT1A1 Ontogeny Qualification",
      "Content": "Content/Section1.md",
      "Sections": []
    },
    {
      "Id": 3,
      "Title": "Chapter 2: Pediatric translation qualification results",
      "Content": "Content/Section3.md",
      "Sections": [
        {
          "Id": 31,
          "Title": "Chapter 2.1: Raltegravir PK Ratio tables and Figures",
          "Content": "Content/Raltegravir_children.md",
          "Sections": []
        },
        {
          "Id": 32,
          "Title": "Chapter 2.2: Raltegravir Concentration-Time profiles in Children",
          "Content": "Content/Concentration_time_profiles_children.md",
          "Sections": []
        }
      ]
    },
    {
      "Id": 4,
      "Title": "Chapter 3: Adult PBPK model building and performance",
      "Content": "Content/Section2.md",
      "Sections": [
        {
          "Id": 40,
          "Title": "Chapter 3.1: Raltegravir Input Tables",
          "Content": "Content/Raltegravir_adults.md",
          "Sections": []
        },
        {
          "Id": 41,
          "Title": "Chapter 3.2: Raltegravir Diagnostics Plots",
          "Content": "Content/Raltegravir_diagnostics.md",
          "Sections": []
        },
        {
          "Id": 42,
          "Title": "Chapter 3.3: Raltegravir Concentration-Time profiles in Adults",
          "Content": "Content/Concentration_time_profiles_adults.md",
          "Sections": []
        }
      ]
    }
  ],
  "Intro": [
    {
      "Path": "Intro/titlepage.md"
    }
  ]
}